Aegea has now raised $96m in overall financing, after securing funds from investors including existing backers Medtronic and BioMed Ventures.

Aegea, the US-based developer of a device to treat endometrial ablation, raised $40m in financing on Tuesday from a consortium featuring medical device maker Medtronic and real estate services provider BioMed Realty.

Hedge fund sponsor Perceptive Advisors invested $30m to lead the round, which included venture capital firms Alloy Ventures, Delphi Ventures and Solas BioVentures, while BioMed participated through corporate venturing subsidiary Biomed Ventures.

Founded in 2008, Aegea has built a water vapour-based device for abnormal uterine bleeding in women,…